<DOC>
	<DOC>NCT00403962</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy, safety and tolerability of a combination of Vestipitant and Paroxetine in patients with Social Anxiety Disorder (SAD)</brief_summary>
	<brief_title>A Combination Therapy In Patients With Social Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>Vestipitant</mesh_term>
	<criteria>Inclusion criteria: Primary diagnosis of Generalised Social Anxiety Disorder as defined in DSMIV. Capable of giving informed consent and willing to comply with the study requirements. Women of childbearing potential must agree to one of a number of defined acceptable methods of birth control. Exclusion criteria: Primary diagnosis within the past 6 months of another Axis 1 disorder such as Major Depression or another anxiety disorder. Use of medications for a psychiatric condition including herbals in the past 212 weeks according to medication type. Subjects who, in the investigator's judgement pose a current, serious suicidal or homicidal risk or have made a suicide attempt within the past 6 months. Subjects who currently meet or who met within 6 months prior to screening DSMIV criteria for substance abuse or subjects who currently meet or who met within 6 months prior to screening DSMIV criteria for substance dependence (other than nicotine). Significantly abnormal blood or urine laboratory tests or electrocardiogram (ECG).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>anxiety</keyword>
	<keyword>Social Anxiety Disorder</keyword>
	<keyword>SAD</keyword>
</DOC>